Pharmaceutical Industry

The pharmaceutical industry discovers, develops, produces, and markets drugs or pharmaceutical drugs for use as medications to be administered (or self-administered) to patients, with the aim to cure them, vaccinate them, or alleviate the symptoms. Pharmaceutical companies may deal in generic or brand medications and medical devices. They are subject to a variety of laws and regulations that govern the patenting, testing, safety, efficacy and marketing of drugs.

Wikipedia

Publications

CADTH: Canadian Agency for Drugs and Technologies in Health · 28 February 2024 English

The organization will review and discuss any feedback received on the preliminary draft with the Chair of the implementation advice panel, who will determine if there is 10 a need …

manufacturer of the technology under review. • Pharmaceutical industry manufacturers are typically the Drug Identification respectively). 6.3. Manufacturer Eligibility Pharmaceutical industry manufacturers are typically the Drug Identification


CADTH: Canadian Agency for Drugs and Technologies in Health · 10 January 2024 English

• In the absence of a cost-effectiveness analysis, and based on cost differences only, the addition of eltrombopag is expected to generate an incremental cost for the publicly funded drug …

Hear From the Pharmaceutical Industry? No input was received from the pharmaceutical industry. What Did We Clinicians? What Did We Hear From the Pharmaceutical Industry? What Did We Hear From Public Drug Programs


CADTH: Canadian Agency for Drugs and Technologies in Health · 4 January 2024 English

59 Why Did CADTH Conduct This Review? 60 Publicly funded drug plans requested this Streamlined Drug Class Review of 61 SGLT2 inhibitors given the emergence of new evidence in cardiorenal …

Guidelines. 87 What Did We Hear From the Pharmaceutical Industry? 88 CADTH received input from two manufacturers


CADTH: Canadian Agency for Drugs and Technologies in Health · 4 January 2024 English

The industry feedback described the strengths and limitations of the NMA 86 and the context around the current treatment landscape. [...] FMEC discussed the daratumumab- publicly available price of daratumumab, …

review. 81 What Did We Hear From the 82 Pharmaceutical Industry? 83 CADTH has received inputs and feedback


CGPA: Canadian Generic Pharmaceutical Association · 18 December 2023 English

The parameters of the study and the results of the research are outlined in this report. [...] Also highlighted are the details of the pCPA/CGPA pricing agreement, the value of …

prescriptions.* Foreword Canada’s generic pharmaceutical industry supports improved access to p rescription


CADTH: Canadian Agency for Drugs and Technologies in Health · 11 December 2023 English

Stakeholder Input

— — X — McGill COE-AD and its — — — X pharmaceutical industry sponsors (Pfizer Canada, AbbVie Canada


AECL: Atomic Energy of Canada Limited · 30 November 2023 English

AECL’s decarbonization and climate resilience Engagement and reconciliation with Indigenous efforts, as aligned with the UN Sustainability Goals peoples and broader community engagement is relating to Industry, Innovation and Infrastructure, …

of nuclear by now bringing together the pharmaceutical industry, academia, and the health sector to capitalize


Council of Canadians · 23 November 2023 English

How we’re flipping the script on universal pharmacare, Canadian Perspectives, Autumn 2023 WRITTEN BY ROBIN TRESS HOW WE’RE FLIPPING THE SCRIPT ON UNIVERSAL PHARMACARE Whether people were learning about pharmacare …

Because pharmacare is an issue that the pharmaceutical industry has purposefully confused and obscured


APF: Asia Pacific Foundation of Canada · 22 November 2023 English

in New York (1995-98), the Embassy of Canada to France, Paris (2001-06 and 2013-14), and the She served as consul general in Mumbai from Mission of Canada to the European …

Our unique business model SECTORS SERVED pharmaceutical industry that has propelled Diex to be conducts


CMA: Canadian Medical Association · 16 November 2023 English

The PMRA considers that residues of in 2017 was based, in the Proposed Re-Evaluation Decision, on glyphosate “will not pose an unacceptable risk to any segment of 118 references to …

Private profits versus public policy: the pharmaceutical industry and ders, prostate cancer, multiple myeloma Transparency, Power, and Influ- ence in the Pharmaceutical Industry. Halifax: Dalhousie University; 2021:114-28


View more